Spirent Positions To Assure Next-Generation Device And Network Performance
Spirent Communications plc (LSE:SPT), the trusted provider of test, measurement, assurance and analytics solutions for next-generation devices and networks, today announced the company-wide “Promise. Assured.” business initiative to leverage its proven innovation to pursue emerging technologies and new industries and extend into service provider and enterprise networks. The company will focus on assuring customer performance and revenues with solutions for 5G, lifecycle service assurance and analytics, and cybersecurity. It will also explore new business opportunities in virtualization, autonomous vehicles and automotive.
“Markets are transforming rapidly and our role in this new frontier is to march alongside our customers, not just as solution providers but true partners,” said Eric Hutchinson, CEO, Spirent. “That means delivering insights that influence and support strategies for revenue growth and cost savings throughout the organizations we serve, as we help accelerate the transition of devices, equipment and applications from the lab into the operational network.”
Spirent’s focus on 5G, lifecycle service assurance and analytics for better customer experiences and cybersecurity to simplify and validate defenses will include solutions for development, benchmarking and management of mobile networks, Ethernet business services, and virtualized network functions. It will see the company working with customers in new ways, leveraging deep expertise and experience in:
- 5G – As 5G investments gain momentum globally, Spirent enables and assures 5G products and services, including hybrid networks. The company will continue to create 5G test solutions for development of 5G devices and network equipment, and expand focus to include service assurance and analytics of 5G networks.
- Lifecycle Service Assurance – As great customer experiences become the next competitive battleground, Spirent will deliver real-time operational analytics to address issues before they impact service performance and customer experience, leveraging automation, analytics and active testing technologies. This includes expanding the company’s VisionWorks solutions to 5G and IoT and incorporating artificial intelligence, machine learning and big data analytics into new applications.
- Cybersecurity – Spirent tests products and networks for security vulnerabilities, offering cybersecurity products that simulate a wide range of scenarios with real world traffic mixes and services that provide industry-leading expertise. The company fosters collaborative industry efforts, including through its work as a founding member of NetSecOPEN, the open industry group that brings together security product vendors, test tool vendors and test labs to develop test specifications. Spirent will expand its security products and services, including new data breach detection assessment capabilities as it accelerates growth in this market.
Spirent is recognized globally as a leader in lab-based high-speed Ethernet, positioning and mobile network infrastructure testing, and service assurance systems for service providers. The company will continue to advance in these markets while innovating toward cybersecurity solutions, and automated testing and development of autonomous service assurance solutions. It will also focus on validating automotive Ethernet performance and evaluating vehicle-to-vehicle, vehicle-to-infrastructure and autonomous vehicle implementation readiness.
The “Promise. Assured.” initiative is supported by a new branding campaign that emphasizes Spirent’s capabilities to bring clarity to increasing device and network complexity, and serve as trusted advisors to help enable and assure the promises Spirent’s customers make to their customers.
Spirent Communications plc. (LSE: SPT) offers test, measurement, analytics and assurance solutions for next-generation devices and networks. The company provides products, services and information for high-speed Ethernet, positioning and mobile network infrastructure markets, with expanding focus on service assurance, cybersecurity and 5G. Spirent is accelerating the transition of connected devices, network equipment and applications from development labs to the operational network, as it continues to innovate toward fully-automated testing and autonomous service assurance solutions.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
In the Wake of the Ongoing Floods in Kerala; UAE Exchange and Unimoni Waive Service Fee on Remittances to Kerala Chief Minister's Distress Relief Fund16.8.2018 09:30 | Pressemelding
Leading money transfer, foreign exchange and payment solutions brands, UAE Exchange and Unimoni, have waived service fee on remittances to Kerala Chief Minister's Distress Relief Fund in the wake of the catastrophic floods that has ravaged the Indian state of Kerala. The initiative which enables the global Indian diaspora to contribute to the relief efforts, follows a personal contribution of two crore rupees made by the Group Chairman and noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty, to help those affected by the floods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180816005229/en/ Promoth Manghat, Executive Director, Finablr and Group CEO (Photo: AETOSWire) Promoth Manghat, Executive Director, Finablr and Group CEO, said, “As a committed corporate citizen, who firmly believes in helping communities in times of need, it was our responsibility to do all that is in our power to aid the peopl
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00 | Pressemelding
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac
Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05 | Pressemelding
Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations
Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40 | Pressemelding
Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per
CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37 | Pressemelding
Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He
Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43 | Pressemelding
SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.